Articles

Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease

Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
Clinical Research Division, Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle, WA, USA
Clinical Research Division, Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle, WA, USA
Clinical Research Division, Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle, WA, USA
Blood and Marrow Transplantation and Cellular Immunotherapy. H. Lee Moffitt Cancer Center and Research Institute. Tampa, FL, USA
Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, USA
Division of Stem Cell Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA, USA
Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
Clinical Research Division, Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle, WA, USA
Division of Hematology, Oncology and Transplantation, University of Minnesota Medical Center, Minneapolis, MN, USA
Haematologica Early view May 26, 2022 https://doi.org/10.3324/haematol.2021.279814